Open Access

[Retracted] Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression

  • Authors:
    • Hongchun Guo
    • Feng Liu
    • Shuguang Yang
    • Tao Xue
  • View Affiliations

  • Published online on: July 15, 2024     https://doi.org/10.3892/ol.2024.14568
  • Article Number: 435
  • Copyright : © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Related Articles

Journal Cover

September-2024
Volume 28 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Guo H, Liu F, Yang S and Xue T: [Retracted] Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression. Oncol Lett 28: 435, 2024.
APA
Guo, H., Liu, F., Yang, S., & Xue, T. (2024). [Retracted] Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression. Oncology Letters, 28, 435. https://doi.org/10.3892/ol.2024.14568
MLA
Guo, H., Liu, F., Yang, S., Xue, T."[Retracted] Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression". Oncology Letters 28.3 (2024): 435.
Chicago
Guo, H., Liu, F., Yang, S., Xue, T."[Retracted] Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression". Oncology Letters 28, no. 3 (2024): 435. https://doi.org/10.3892/ol.2024.14568